Buscar resultados de ensayos clínicos
Philadelphia Chromosome - 26 Studies Found
Estado | Estudiar |
Recruiting |
Nombre del estudio: A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young Adults Condición: Philadelphia Chromosome Positive Adult Acute Lymphoblastic Leukemia Fecha: 2015-11-19 Intervenciones:
|
Recruiting |
Nombre del estudio: Multicenter Trial Treatment of Philadelphia Chromosome Negative B-cell Acute Lymphoblastic Leukemia of Young Adults Condición: Philadelphia Chromosome Negative Adult B-cell Acute Lymphoblastic Leukemia Fecha: 2015-11-25 |
Suspended |
Nombre del estudio: Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+) Condición: Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+) Fecha: 2010-10-15 Intervenciones: Drug: Imatinib Mesylate patient will receive Imatinib (Glivec®), 300 mg/m²/day, per oral, in c |
Suspended |
Nombre del estudio: Phase II Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Chronic Myeloid Leukemia (CML) Philadelphia Chromosome-positive (Ph+) Condición: Chronic Myeloid Leukemia (CML) With Philadelphia Chromosome-positive (Ph+) Fecha: 2010-10-14 Intervenciones: Drug: Imatinib Mesylate Patient will receive Imatinib Mesylate, continuous-use, 260 mg/m2/day dose, maxi |
Terminated |
Nombre del estudio: Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Condición:
|
Terminated |
Nombre del estudio: TKI Therapy Based on Molecular Monitoring in Allogeneic-HSCT Recipients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia Condición:
|
Recruiting |
Nombre del estudio: Intravenous Erwinia Chrysanthemi Asparaginase in Patients With Newly Diagnosed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Aged 60 Years or Older Condición:
|
Completed |
Nombre del estudio: Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response Condición:
|
Completed |
Nombre del estudio: Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome & /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase Condición: CML in Chronic Phase Fecha: 2010-02-01 Intervenciones: Drug: Nilotinib Nilotinib was supplied by Novartis as 150 mg hard gelatin capsules in bottles. Nilotinib |
Terminated |
Nombre del estudio: Growth Factor Signature (GFS) Pilot Study (MK0000-098)(COMPLETED) Condición:
Intervenciones: Other: Comparator: Biomarker evaluation Patients on standa |